Clinical trialObservationalActive not recruiting
Tempus Priority Study: A Pan-tumor Observational Study
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Active not recruiting
- Study type
- Observational
- Start
- 19 October 2020
- Expected end
- 19 October 2030
- Enrollment
- 1,000 participants
- Sites
- 2
- Primary outcomes
- Create robust data set of health information
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 6 May 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Detailed description public domain (ClinicalTrials.gov)
The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.